Global Digital Signature Market to Reach $2,934.6 Million by 2023     |    Global Outdoor Lighting Market to Witness 8.4% CAGR during 2017 - 2023     |    Oral Mucositis Therapeutics Pipeline to Receive More Drug Designations from the USFDA in the Coming Years

Toll Free (US/Canada): 1-888-778-7886

INT'L: 1-347-960-6455

enquiry@psmarketresearch.com

Herpes Simplex Virus Infections Therapeutic Pipeline Shows Enormous Growth in the Future

Herpes Simplex Virus Infections Therapeutic Pipeline Shows Enormous Growth in the Future

May 2017

According to a new research report “Herpes simplex virus infections Therapeutic Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Herpes simplex virus infections Therapeutic pipeline currently exhibits a pipeline with 20 drug candidates.

Access More About This Research at: https://www.psmarketresearch.com/market-analysis/hsv-infections-therapeutics-pipeline-analysis

Herpes simplex virus infections Therapeutic pipeline in 2017

The study analysed that the Herpes simplex virus infections pipeline comprises of 20 drug candidates, of which one drug candidate is in Phase III stage, five drug candidates are in Phase II stage, three drug candidates are in Phase I stage, eight drug candidates are in Pre-Clinical stage, three candidates are in discovery Phase. Herpes is an infection caused by a virus known as, herpes simplex virus. It is estimated that around 3.7 billion people under the age of 50 years are suffering with the herpes simplex virus infection, globally. The disease is categorized into two types: HSV1 and HSV2. HSV1, also known as oral herpes can lead to sores on the mouth and around the lips. HSV2 causes genital herpes, and is a sexually-transmitted virus which is a leading cause of recurrent genital herpes worldwide. Various new therapies and advanced technologies are driving the growth of Herpes simplex virus infections pipeline.

Insights on pipeline segments

As per the findings of the research, around 20.0% of drug candidates for the treatment of Herpes simplex virus infections Therapeutic pipeline are being developed to be administered by oral route,15.0% by intravenous route, 40.0% are not disclosed and 25.0% are to be administered by other routes which includes sublingual, intramuscular and Topical.

New innovating technologies offer development of promising drugs

Many technologies are being developed that offer promising innovative treatments which can control the progression of Herpes simplex virus infections such as, Vector based technology platform, AdenoVerse technology platform, Juvari’s technology platform and Nanostat technology platform. AdenoVerse technology platform includes a broad range of adenovirus vectors for efficient gene delivery for therapeutics and vaccines as well as proven scale-up and production methodologies and proprietary manufacturing cell lines. All these technologies are important for developing of drugs for the treatment of Herpes simplex virus infections.

Major companies collaborate for the development of Herpes simplex virus infections Pipeline

The research also found that various companies have collaborated for the development of Herpes simplex virus infections pipeline. In July 2013, NanoBio Corporation entered into an agreement with the Division of Microbiology and Infectious Diseases (DMID), a division of National Institute of Health. Under the agreement, DMID agreed to fund certain activities and studies in support of developing intranasal and intramuscular nanoemulsion vaccines for HSV-2. In June 2014, - PaxVax Inc., entered into a research and development collaboration with the University of California to develop a combination vaccine to prevent genital herpes simplex virus infections.

Some of the key players developing drugs for the treatment ofHerpes virus simplex infections include Maruho Co., Ltd., NanoBio Corporation, Lumavita AG, Shulov Innovate for Science Ltd. 2012, Beech Tree Labs, Inc.,Sanofi Pasteur, PaxVax Inc.,Vical, Inc., Immune Design Corp., Profectus BioSciences, Inc., Editas Medicine, Inc., GenVec, Inc., ViRAZE,  JN-International Medical Corporation and AiCuris Anti-infective Cures GmbH.

Herpes Simplex Virus Infections Therapeutics Pipeline Analysis

  • By Phase
    • Phase III
    • Phase II
    • Phase I
    • Pre-Clinical
    • Discovery
  • By Route of Administration
    • Not Disclosed
    • Oral
    • Intravenous
    • Others
  • By Molecule Type
    • Vaccines
    • Small Molecule
    • Others
  • By Company

LATEST PUBLICATIONS BY P&S

  • Smart Parking Systems Market

    P&S Market Research - Smart Parking Systems Market report Market Overview Smart parking systems help the vehicle user to find the nearest parking space and provides information ... Continue Reading
  • Automotive Drivetrain Market

    P&S Market Research - Automotive Drivetrain Market report Market Overview The automotive drivetrain is a system that act as medium to connect the transmission to the drive axles... Continue Reading
  • Lysosomal Storage Disorder Therapeutics Pipeline Analysis

    P&S Market Research - Lysosomal Storage Disorders Pipeline Analysis report Disease Overview Lysosomal storage disorder refers to inherited metabolic disorders that are characterize by enzyme def... Continue Reading
  • Spinal Muscular Atrophy (SMA) Therapeutics Pipeline Analysis

    P&S Market Research - Spinal Muscular Atrophy Therapeutics Pipeline Analysis report Disease Overview Spinal muscular atrophy is a rare inherited genetic disease that is characterized by loss of nerve cel... Continue Reading
  • Scar Treatment Market

    P&S Market Research - Scar Treatment Market report Market Overview Scar treatment in the study refers to the treatment of marks on the skin surface, that appear when the ... Continue Reading

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Address : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment